开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2016-08-17 ms6134842258072312

一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。

101 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2022-04-19 神的女儿

2.4提交
2.7修改单位邮箱和ORCID
至今一直Under Review

93 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2022-07-18 ms8000000220191370

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：细胞生物学机制
经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。

104 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2022-07-18 ms8000000220191370

审稿速度:6.0 | 投稿命中率:25.0
经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2019-03-25 ms8120435325541008

关于这个杂志没有找到太多投稿相关记录，因此记录一下
2月26日投稿
3月25日依然是under review的状态
不管结果如何，先记录一下

206 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2021-12-29 msSSSSSD

前两个关键词如何选择？

113 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2021-12-29 桑晒麦拉

关键词和题目的关系？

109 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2021-01-25 Xiong、

投稿提交过后就是under review，怎么知道有没有送外审？

172 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2019-04-09 ms9526231670310936

审稿速度:12.0 | 投稿命中率:75.0
经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下
2月26日投稿
3月25日依然是under review的状态
4月1日 with monitoring editor for decision
现在是4月9日还是with monitoring editor for decision
不管结果如何，先记录一下

185 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=833153, encodeId=ff6883315386, content=一个月审稿，3个reviewer，有一个水平很高，能提升文章，30来个问题， 3个月大修补实验，静候结果。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=069a5414125, createdName=ms6134842258072312, createdTime=Wed Aug 17 17:24:28 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212630, encodeId=70321212630f3, content=2.4提交 2.7修改单位邮箱和ORCID 至今一直Under Review , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21935563242, createdName=神的女儿, createdTime=Tue Apr 19 19:48:47 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233201, encodeId=d4651233201d3, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学机制 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:54:11 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233202, encodeId=0044123320227, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：这个杂志是老牌细胞生物学期刊，感觉有难度，在细胞生物学方向可能和JMB或JBC差不多档次，甚至要求更高一些，我们的文章JCB都能送审，这个杂志竟然直接拒稿。且上面中国人的文章很少。编辑要求分子机制必须非常新颖且深入，而且拒稿邮件直接说每年只接收20%左右的投稿文章，虽然你们的文章工作不错很全面但是不能满足它们的什么什么blablabla。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8a275587958, createdName=ms8000000220191370, createdTime=Mon Jul 18 14:56:47 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850465, encodeId=a8438504659d, content=关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=893e5414041, createdName=ms8120435325541008, createdTime=Mon Mar 25 09:58:31 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092691, encodeId=7cce109269111, content=前两个关键词如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092692, encodeId=a97e109269243, content=关键词和题目的关系？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919657, encodeId=3caf91965e9d, content=投稿提交过后就是under review，怎么知道有没有送外审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210125/811b62ca6ad741f880d91651421fdcc3/98477d9fc3f3429b9e21b4025bf179c9.jpg, createdBy=26a32140578, createdName=Xiong、, createdTime=Mon Jan 25 11:01:59 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850721, encodeId=d20b850e2167, content=审稿速度:12.0 | 投稿命中率:75.0 经验分享：关于这个杂志没有找到太多投稿相关记录，因此记录一下 2月26日投稿 3月25日依然是under review的状态 4月1日 with monitoring editor for decision 现在是4月9日还是with monitoring editor for decision 不管结果如何，先记录一下 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=ms9526231670310936, createdTime=Tue Apr 09 10:38:10 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585611, encodeId=703758561162, content=请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表: 你好，请问这个问题你是怎么解决的？, beContent=淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fe1d1672319, createdName=1de14753m02(暂无匿称), createdTime=Sat Feb 29 00:00:00 CST 2020, time=2020-02-29, status=1, ipAttribution=)]

2020-02-29 1de14753m02(暂无匿称)

请问你也遇到了这个问题吗？解决了吗？今天投稿一直search 不出ORCHID ID。淡如水的优雅23 2020-02-19 发表::
你好，请问这个问题你是怎么解决的？淡如水的优雅23 2020-02-19 00:00:00 发表:
你好，请问这个问题你是怎么解决的？

淡如水的优雅23 2020-02-19 发表:: 你好，请问这个问题你是怎么解决的？

19 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务